Valeant Libido Drug Sales Claims Cut In Half

Two of four counts will go forward in a stockholder suit accusing Valeant Pharmaceuticals International Inc. of bungling the marketing of a merger partner's potential breakthrough female libido drug, a Delaware...

Already a subscriber? Click here to view full article